Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03921021
Recruitment Status : Recruiting
First Posted : April 19, 2019
Last Update Posted : May 30, 2019
Sponsor:
Collaborator:
Oncolys BioPharma Inc
Information provided by (Responsible Party):
Weill Medical College of Cornell University

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : March 28, 2021
  Estimated Study Completion Date : March 28, 2022